Compliance Rate

Compliance Rate 50.0%
Compliant submissions 1
Incompliant submissions 1
Total trials 2

My Organizations' Clinical Trials

Showing 3499 of 3499 entries
View as:

The Effect of Oral Candidiasis on the Speech Production, Feeding Skills, and Self-Concept of Children and Adolescents With Symptomatic HIV Infection

Phase: N/A Priority: Normal
NCT ID: NCT00001448 Org: User:
Start: 08/31/95 End: 06/30/00 Due: 06/30/01

Daratumumab, Bortezomib, and Dexamethasone With or Without Venetoclax in Treating Patients With Relapsed or Refractory Multiple Myeloma

Phase: N/A Priority: Normal
NCT ID: NCT03701321 Org: User:
Start: 01/25/19 End: 05/28/20 Due: 05/28/21

17-AAG and Sorafenib in Treating Patients With Unresectable or Metastatic Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT00121264 Org: User:
Start: 03/31/05 End: 07/31/10 Due: 07/31/11

BLAST MRD AML-1: BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia 1- A Randomized Phase 2 Study of Anti-PD-1 Pembrolizumab in Combination With Intensive Chemotherapy as Frontline Therapy in Patients With Acute Myeloid Leukemia

Phase: N/A Priority: Normal
NCT ID: NCT04214249 Org: User:
Start: 02/17/21 End: 01/30/26 Due: 01/30/27

Interleukin-12 Plus Interleukin-2 in Treating Patients With Advanced Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT00005604 Org: User:
Start: 03/31/00 End: - Due: -

Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial)

Phase: N/A Priority: Normal
NCT ID: NCT03233204 Org: User:
Start: 09/14/17 End: 06/30/24 Due: 06/30/25

SB-715992 in Treating Patients With Recurrent or Metastatic Head and Neck Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00095628 Org: User:
Start: 01/31/05 End: 07/31/10 Due: 07/31/11

FOLFIRI or Modified FOLFIRI and Veliparib as Second Line Therapy in Treating Patients With Metastatic Pancreatic Cancer

Phase: N/A Priority: Normal
NCT ID: NCT02890355 Org: User:
Start: 09/01/16 End: 03/17/26 Due: 03/17/27

Genetic Component of Handedness

Phase: N/A Priority: Normal
NCT ID: NCT00005003 Org: User:
Start: 03/31/00 End: 04/30/06 Due: 04/30/07

Studies of Patients With Skin Disease, Patients With Neurological Degenerations, and Normal Volunteers

Phase: N/A Priority: Normal
NCT ID: NCT00001164 Org: User:
Start: 07/31/78 End: 06/30/00 Due: 06/30/01

Testing Olaparib and Temozolomide Versus the Usual Treatment for Uterine Leiomyosarcoma After Chemotherapy Has Stopped Working

Phase: N/A Priority: Normal
NCT ID: NCT05432791 Org: User:
Start: 03/30/23 End: 03/09/30 Due: 03/09/31

Testing A New Anti-cancer Drug Combination, Entinostat and ZEN003694, for Advanced and Refractory Solid Tumors and Lymphomas

Phase: N/A Priority: Normal
NCT ID: NCT05053971 Org: User:
Start: 11/16/22 End: 07/01/25 Due: 07/01/26

Biomarker Analysis of Central Nervous System Tumors

Phase: N/A Priority: Normal
NCT ID: NCT02692898 Org: User:
Start: 02/25/16 End: 11/15/19 Due: 11/15/20

Oblimersen in Treating Patients With Merkel Cell Carcinoma

Phase: N/A Priority: Normal
NCT ID: NCT00079131 Org: User:
Start: 01/31/04 End: - Due: -

Vaccine and Chemotherapy for Previously Untreated Metastatic Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00048893 Org: User:
Start: 11/30/02 End: 06/30/11 Due: 06/30/12

Ifosfamide With or Without O(6)-Benzylguanine in Treating Patients With Unresectable, Metastatic Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT00086970 Org: User:
Start: 06/30/04 End: - Due: -

Vaccine Therapy Plus Sargramostim and Chemotherapy in Treating Women With Stage II or Stage III Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00052351 Org: User:
Start: 09/30/02 End: 10/31/07 Due: 10/31/08

Simvastatin in Preventing Liver Cancer in Patients With Liver Cirrhosis

Phase: N/A Priority: Normal
NCT ID: NCT02968810 Org: User:
Start: 06/21/17 End: 12/23/25 Due: 12/23/26

Pazopanib Hydrochloride in Treating Patients With Stage IV or Recurrent Nasopharyngeal Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00454142 Org: User:
Start: 08/31/07 End: 08/31/10 Due: 08/31/11

BAY 43-9006 Plus Cetuximab to Treat Colorectal Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00326495 Org: User:
Start: 05/10/06 End: 11/07/14 Due: 11/07/15

Vemurafenib and White Blood Cell Therapy for Advanced Melanoma

Phase: N/A Priority: Normal
NCT ID: NCT01585415 Org: User:
Start: 04/09/12 End: 07/21/16 Due: 07/21/17

Atezolizumab in Treating Patients With Recurrent BCG-Unresponsive Non-muscle Invasive Bladder Cancer

Phase: N/A Priority: Normal
NCT ID: NCT02844816 Org: User:
Start: 03/13/17 End: 06/26/24 Due: 06/26/25

Testing the Combination of Anti-cancer Drugs Tiragolumab and Atezolizumab to Improve Outcomes for Patients With Recurrent Glioblastoma

Phase: N/A Priority: Normal
NCT ID: NCT06328036 Org: User:
Start: 04/30/25 End: 07/01/25 Due: 07/01/26

Trametinib in Increasing Tumoral Iodine Incorporation in Patients With Recurrent or Metastatic Thyroid Cancer

Phase: N/A Priority: Normal
NCT ID: NCT02152995 Org: User:
Start: 08/14/14 End: 01/25/26 Due: 01/25/27